title: [Clinical evaluation of intraperitoneal hyperthermic perfusion in far-advanced gastric cancer].
abstract: Nineteen far-advanced gastric cancer patients, including peritoneal dissemination, underwent surgical treatment followed by intraperitoneal hyperthermic perfusion (IPHP). Seven of them had cancerous ascites, 5 had ovarial metastasis, and in 7 the primary tumor extended to the adjacent organs. Postoperatively, ascitic effusion was absent after IPHP, and all patients were discharged. The survival of the IPHP group was compared with that of 27 advanced gastric cancer patients with serosal invasion (control group), who underwent gastrectomy without IPHP. In the IPHP group, the average and 50% survival was 400 and 520 days, respectively, and 1-year survival rate was 73.3%, against 273 days, 250 days, and 31.8%, respectively, in controls. The survival rate for the IPHP group was statistically better than that of the control group (p less than 0.01). In patients with peritoneal dissemination, the average survival and 50% survival for the IPHP group was 396 and 380 days, respectively, and 1-year survival rate was 62.5%, against 204 days, 170 days, and 16.6%, respectively, in controls. Based on these results, IPHP was suggested to be effective for gastric cancer with serosal invasion, especially with peritoneal dissemination.
authors.affiliation: First Dept. of Surgery, School of Medicine, Chiba University.
authors.forename: S
authors.initials: S
authors.lastname: Kiuchi
authors.forename: S
authors.initials: S
authors.lastname: Fujimoto
authors.forename: R D
authors.initials: RD
authors.lastname: Shrestha
authors.forename: M
authors.initials: M
authors.lastname: Kokubun
authors.forename: K
authors.initials: K
authors.lastname: Kobayashi
authors.forename: C
authors.initials: C
authors.lastname: Konno
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
authors.forename: K
authors.initials: K
authors.lastname: Okui
mesh_terms: D000328:Adult; D000368:Aged; D010478:Chemotherapy, Cancer, Regional Perfusion; D003131:Combined Modality Therapy; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage / Q000627:therapeutic use; D010529:Peritoneal Cavity; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000628:therapy; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*
chemical_list: D008937:Mitomycins; D016685:Mitomycin